Investors who own more than 5% of a class must file a Schedule 13D or 13G. The latest filing for each security since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Corbus Pharmaceuticals Holdings, Inc.
13G
CRBP · 21833P301
|
9.9% |
9/30/2026
Event 9/23/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
BetterLife Pharma Inc.
13G
BETRF · 08772P202
|
9.0% |
9/22/2026
Event 9/15/2026
|
|||
| RA Capital Management, L.P. | 9.0% | ||||
| Peter Kolchinsky | 9.0% | ||||
| Rajeev Shah | 9.0% | ||||
| RA Capital Healthcare Fund, L.P. | 9.0% | ||||
|
Sionna Therapeutics, Inc.
13D/A
SION · 829401108
|
14.3% |
9/21/2026
Event 9/17/2026
|
|||
| RA Capital Management, L.P. | 14.3% | ||||
| Peter Kolchinsky | 14.3% | ||||
| Rajeev Shah | 14.3% | ||||
| RA Capital Healthcare Fund, L.P. | 7.6% | ||||
| RA Capital Nexus Fund III, L.P. | 4.9% | ||||
|
Tyra Biosciences, Inc.
13D/A
TYRA · 90240B106
|
19.9% |
9/17/2026
Event 9/15/2026
|
|||
| RA Capital Management, L.P. | 19.9% | ||||
| Peter Kolchinsky | 19.9% | ||||
| Rajeev Shah | 19.9% | ||||
| RA Capital Healthcare Fund, L.P. | 17.2% | ||||
|
JATT III Acquisition Corp
13G
G5080G109
|
5.1% |
9/3/2026
Event 8/27/2026
|
|||
| RA Capital Management, L.P. | 5.1% | ||||
| Peter Kolchinsky | 5.1% | ||||
| Rajeev Shah | 5.1% | ||||
| RA Capital Healthcare Fund, L.P. | 5.1% | ||||
|
Latigo Biotherapeutics, Inc.
13G
LTGO · 517954103
|
8.4% |
8/17/2026
Event 8/10/2026
|
|||
| RA Capital Management, L.P. | 8.4% | ||||
| Peter Kolchinsky | 8.4% | ||||
| Rajeev Shah | 8.4% | ||||
| RA Capital Healthcare Fund, L.P. | 8.4% | ||||
|
GH Research PLC
13G/A
GHRS · G3855L106
|
7.1% |
8/14/2026
Event 8/12/2026
|
|||
| RA Capital Management, L.P. | 7.1% | ||||
| Peter Kolchinsky | 7.1% | ||||
| Rajeev Shah | 7.1% | ||||
| RA Capital Healthcare Fund, L.P. | 6.9% | ||||
|
Septerna, Inc.
13D/A
SEPN · 81734D104
|
11.8% |
8/14/2026
Event 8/12/2026
|
|||
| RA Capital Management, L.P. | 11.8% | ||||
| Peter Kolchinsky | 11.8% | ||||
| Rajeev Shah | 11.8% | ||||
| RA Capital Healthcare Fund, L.P. | 10.2% | ||||
|
Taysha Gene Therapies, Inc.
13G/A
TSHA · 877619106
|
9.9% |
8/14/2026
Event 6/30/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Rani Therapeutics Holdings, Inc.
13G/A
RANI · 753018100
|
9.9% |
8/14/2026
Event 6/30/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Ovid Therapeutics Inc.
13G/A
OVID · 690469101
|
9.9% |
8/14/2026
Event 6/30/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Karyopharm Therapeutics Inc.
13G/A
KPTI · 48576U205
|
9.9% |
8/14/2026
Event 6/30/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Geron Corporation
13G/A
GERN · 374163103
|
9.9% |
8/14/2026
Event 6/30/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Fulcrum Therapeutics, Inc.
13G/A
FULC · 359616109
|
0% |
8/14/2026
Event 6/30/2026
|
|||
| RA Capital Management, L.P. | 0% | ||||
| Peter Kolchinsky | 0% | ||||
| Rajeev Shah | 0% | ||||
| RA Capital Healthcare Fund, L.P. | 0% | ||||
|
Edgewise Therapeutics, Inc.
13G/A
EWTX · 28036F105
|
7.8% |
8/14/2026
Event 6/30/2026
|
|||
| RA Capital Management, L.P. | 7.8% | ||||
| Peter Kolchinsky | 7.8% | ||||
| Rajeev Shah | 7.8% | ||||
| RA Capital Healthcare Fund, L.P. | 7.8% | ||||
|
CervoMed Inc.
13G/A
CRVO · 15713L109
|
8.6% |
8/14/2026
Event 6/30/2026
|
|||
| RA Capital Management, L.P. | 8.6% | ||||
| Peter Kolchinsky | 8.6% | ||||
| Rajeev Shah | 8.6% | ||||
| RA Capital Healthcare Fund, L.P. | 8.6% | ||||
|
C4 Therapeutics, Inc.
13G/A
CCCC · 12529R107
|
9.9% |
8/14/2026
Event 6/30/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
BioCryst Pharmaceuticals, Inc.
13G/A
BCRX · 09058V103
|
6.2% |
8/14/2026
Event 6/30/2026
|
|||
| RA Capital Management, L.P. | 6.2% | ||||
| Peter Kolchinsky | 6.2% | ||||
| Rajeev Shah | 6.2% | ||||
| RA Capital Healthcare Fund, L.P. | 6.2% | ||||
|
Avalo Therapeutics, Inc.
13G/A
AVTX · 05338F306
|
6.3% |
8/14/2026
Event 6/30/2026
|
|||
| RA Capital Management, L.P. | 6.3% | ||||
| Peter Kolchinsky | 6.3% | ||||
| Rajeev Shah | 6.3% | ||||
| RA Capital Healthcare Fund, L.P. | 6.3% | ||||
|
Atrium Therapeutics, Inc.
13G/A
RNA · 04965N104
|
0% |
8/14/2026
Event 6/30/2026
|
|||
| RA Capital Management, L.P. | 0% | ||||
| Peter Kolchinsky | 0% | ||||
| Rajeev Shah | 0% | ||||
| RA Capital Healthcare Fund, L.P. | 0% | ||||
|
Adicet Bio, Inc.
13G/A
ACET · 007002207
|
9.9% |
8/14/2026
Event 6/30/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Aclaris Therapeutics, Inc.
13G/A
ACRS · 00461U105
|
9.1% |
8/14/2026
Event 6/30/2026
|
|||
| RA Capital Management, L.P. | 9.1% | ||||
| Peter Kolchinsky | 9.1% | ||||
| Rajeev Shah | 9.1% | ||||
| RA Capital Healthcare Fund, L.P. | 9.1% | ||||
|
TCGX Acquisition Corp.
13G
TCGX · G8708J109
|
5.5% |
8/13/2026
Event 8/6/2026
|
|||
| RA Capital Management, L.P. | 5.5% | ||||
| Peter Kolchinsky | 5.5% | ||||
| Rajeev Shah | 5.5% | ||||
| RA Capital Healthcare Fund, L.P. | 5.5% | ||||
|
Wave Life Sciences, Inc.
13D/A
WVE · 94352A104
|
16.8% |
8/11/2026
Event 8/7/2026
|
|||
| RA Capital Management, L.P. | 16.8% | ||||
| Peter Kolchinsky | 16.8% | ||||
| Rajeev Shah | 16.8% | ||||
| RA Capital Healthcare Fund, L.P. | 16.7% | ||||
|
SAB Biotherapeutics, Inc.
13D/A
SABS · 78397T202
|
9.9% |
8/10/2026
Event 8/6/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Obsidian Therapeutics, Inc.
13G
OBX · 67448A106
|
9.7% |
8/10/2026
Event 8/3/2026
|
|||
| RA Capital Management, L.P. | 9.7% | ||||
| Peter Kolchinsky | 9.7% | ||||
| Rajeev Shah | 9.7% | ||||
| RA Capital Healthcare Fund, L.P. | 8.0% | ||||
|
Inovio Pharmaceuticals, Inc.
13G
INO · 45773H409
|
9.9% |
8/7/2026
Event 7/31/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
DBV Technologies S.A.
13G
DBVT · 23306J309
|
5.8% |
8/6/2026
Event 7/30/2026
|
|||
| RA Capital Management, L.P. | 5.8% | ||||
| Peter Kolchinsky | 5.8% | ||||
| Rajeev Shah | 5.8% | ||||
| RA Capital Healthcare Fund, L.P. | 5.8% | ||||
|
Scribe Therapeutics Inc.
13G
SCTX · 811033109
|
9.6% |
8/3/2026
Event 7/27/2026
|
|||
| RA Capital Management, L.P. | 9.6% | ||||
| Peter Kolchinsky | 9.6% | ||||
| Rajeev Shah | 9.6% | ||||
| RA Capital Healthcare Fund, L.P. | 9.1% | ||||
|
Capricor Therapeutics, Inc.
13G
CAPR · 14070B309
|
5.2% |
8/3/2026
Event 7/27/2026
|
|||
| RA Capital Management, L.P. | 5.2% | ||||
| Peter Kolchinsky | 5.2% | ||||
| Rajeev Shah | 5.2% | ||||
| RA Capital Healthcare Fund, L.P. | 5.2% | ||||
|
Inhibikase Therapeutics, Inc.
13G/A
IKT · 45719W205
|
9.9% |
7/31/2026
Event 7/29/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Artiva Biotherapeutics, Inc.
13D/A
ARTV · 04317A107
|
37.9% |
7/23/2026
Event 7/22/2026
|
|||
| RA Capital Management, L.P. | 37.9% | ||||
| Peter Kolchinsky | 37.9% | ||||
| Rajeev Shah | 37.9% | ||||
| RA Capital Healthcare Fund, L.P. | 35.5% | ||||
|
Freenome, Inc.
13D/A
FRNM · 35661P100
|
14.3% |
7/22/2026
Event 7/20/2026
|
|||
| RA Capital Management, L.P. | 14.3% | ||||
| Peter Kolchinsky | 14.3% | ||||
| Rajeev Shah | 14.3% | ||||
| RA Capital Healthcare Fund, L.P. | 11.4% | ||||
|
Vor Biopharma Inc.
13D/A
VOR · 929033207
|
19.9% |
7/21/2026
Event 7/16/2026
|
|||
| RA Capital Management, L.P. | 19.9% | ||||
| Peter Kolchinsky | 19.9% | ||||
| Rajeev Shah | 19.9% | ||||
| RA Capital Healthcare Fund, L.P. | 19.9% | ||||
|
Agenus Inc.
13G
AGEN · 00847G804
|
9.9% |
7/20/2026
Event 7/13/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Climb Bio, Inc.
13D/A
CLYM · 28658R106
|
33.0% |
7/7/2026
Event 7/2/2026
|
|||
| RA Capital Management, L.P. | 33.0% | ||||
| Peter Kolchinsky | 33.0% | ||||
| Rajeev Shah | 33.0% | ||||
| RA Capital Healthcare Fund, L.P. | 24.1% | ||||
| RA Capital Nexus Fund III, L.P. | 6.4% | ||||
|
Werewolf Therapeutics, Inc.
13D/A
HOWL · 95075A107
|
4.1% |
7/2/2026
Event 6/30/2026
|
|||
| RA Capital Management, L.P. | 4.1% | ||||
| Peter Kolchinsky | 4.1% | ||||
| Rajeev Shah | 4.1% | ||||
| RA Capital Healthcare Fund, L.P. | 3.8% | ||||
|
Solid Biosciences Inc.
13D/A
SLDB · 83422E204
|
11.9% |
6/24/2026
Event 6/22/2026
|
|||
| RA Capital Management, L.P. | 11.9% | ||||
| Peter Kolchinsky | 11.9% | ||||
| Rajeev Shah | 11.9% | ||||
| RA Capital Healthcare Fund, L.P. | 11.8% | ||||
|
Parabilis Medicines, Inc.
13D
PBLS · 698955101
|
23.8% |
6/18/2026
Event 6/11/2026
|
|||
| RA Capital Management, L.P. | 23.8% | ||||
| Peter Kolchinsky | 23.8% | ||||
| Rajeev Shah | 23.8% | ||||
| RA Capital Healthcare Fund, L.P. | 21.6% | ||||
|
Q32 Bio Inc.
13G
QTTB · 746964105
|
9.8% |
6/4/2026
Event 5/28/2026
|
|||
| RA Capital Management, L.P. | 9.8% | ||||
| Peter Kolchinsky | 9.8% | ||||
| Rajeev Shah | 9.8% | ||||
| RA Capital Healthcare Fund, L.P. | 9.8% | ||||
|
Editas Medicine, Inc.
13G
EDIT · 28106W103
|
5.8% |
6/3/2026
Event 5/27/2026
|
|||
| RA Capital Management, L.P. | 5.8% | ||||
| Peter Kolchinsky | 5.8% | ||||
| Rajeev Shah | 5.8% | ||||
| RA Capital Healthcare Fund, L.P. | 5.8% | ||||
|
Sana Biotechnology, Inc.
13G
SANA · 799566104
|
6.3% |
5/21/2026
Event 5/14/2026
|
|||
| RA Capital Management, L.P. | 6.3% | ||||
| Peter Kolchinsky | 6.3% | ||||
| Rajeev Shah | 6.3% | ||||
| RA Capital Healthcare Fund, L.P. | 6.3% | ||||
|
Vaxcyte, Inc.
13G/A
PCVX · 92243G108
|
8.9% |
5/15/2026
Event 3/31/2026
|
|||
| RA Capital Management, L.P. | 8.9% | ||||
| Peter Kolchinsky | 8.9% | ||||
| Rajeev Shah | 8.9% | ||||
| RA Capital Healthcare Fund, L.P. | 8.7% | ||||
|
Unicycive Therapeutics, Inc.
13G/A
UNCY · 90466Y202
|
9.9% |
5/15/2026
Event 3/31/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Palisade Bio, Inc.
13G/A
PALI · 696389402
|
9.9% |
5/15/2026
Event 3/31/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Invivyd, Inc.
13G/A
IVVD · 00534A102
|
7.0% |
5/15/2026
Event 3/31/2026
|
|||
| RA Capital Management, L.P. | 7.0% | ||||
| Peter Kolchinsky | 7.0% | ||||
| Rajeev Shah | 7.0% | ||||
| RA Capital Healthcare Fund, L.P. | 7.0% | ||||
|
Dianthus Therapeutics, Inc.
13G/A
DNTH · 252828108
|
4.8% |
5/15/2026
Event 3/31/2026
|
|||
| RA Capital Management, L.P. | 4.8% | ||||
| Peter Kolchinsky | 4.8% | ||||
| Rajeev Shah | 4.8% | ||||
| RA Capital Healthcare Fund, L.P. | 4.8% | ||||
|
Contineum Therapeutics, Inc.
13G/A
CTNM · 21217B100
|
4.0% |
5/15/2026
Event 3/31/2026
|
|||
| RA Capital Management, L.P. | 4.0% | ||||
| Peter Kolchinsky | 4.0% | ||||
| Rajeev Shah | 4.0% | ||||
| RA Capital Healthcare Fund, L.P. | 4.0% | ||||
|
Avidity Biosciences, Inc.
13G/A
RNAM · 05370A108
|
0% |
5/15/2026
Event 3/31/2026
|
|||
| RA Capital Management, L.P. | 0% | ||||
| Peter Kolchinsky | 0% | ||||
| Rajeev Shah | 0% | ||||
| RA Capital Healthcare Fund, L.P. | 0% | ||||
|
4D Molecular Therapeutics, Inc.
13G/A
FDMT · 35104E100
|
9.9% |
5/15/2026
Event 3/31/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Hemab Therapeutics Holdings, Inc.
13G
COAG · 423494103
|
16.6% |
5/11/2026
Event 5/4/2026
|
|||
| RA Capital Management, L.P. | 16.6% | ||||
| Peter Kolchinsky | 16.6% | ||||
| Rajeev Shah | 16.6% | ||||
| RA Capital Healthcare Fund, L.P. | 13.6% | ||||
|
Altimmune, Inc.
13G
ALT · 02155H200
|
6.5% |
5/1/2026
Event 4/24/2026
|
|||
| RA Capital Management, L.P. | 6.5% | ||||
| Peter Kolchinsky | 6.5% | ||||
| Rajeev Shah | 6.5% | ||||
| RA Capital Healthcare Fund, L.P. | 6.5% | ||||
|
Prelude Therapeutics Incorporated
13G
PRLD · 74065P101
|
9.9% |
4/28/2026
Event 4/21/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
JATT II Acquisition Corp
13G
JATT · G50765109
|
6.4% |
4/27/2026
Event 4/20/2026
|
|||
| RA Capital Management, L.P. | 6.4% | ||||
| Peter Kolchinsky | 6.4% | ||||
| Rajeev Shah | 6.4% | ||||
| RA Capital Healthcare Fund, L.P. | 6.4% | ||||
|
Acrivon Therapeutics, Inc.
13D/A
ACRV · 004890109
|
28.8% |
4/23/2026
Event 4/22/2026
|
|||
| RA Capital Management, L.P. | 28.8% | ||||
| Peter Kolchinsky | 28.8% | ||||
| Rajeev Shah | 28.8% | ||||
| RA Capital Healthcare Fund, L.P. | 27.7% | ||||
|
Wave Life Sciences Ltd.
13D/A
WVE · Y95308105
|
17.1% |
4/17/2026
Event 4/15/2026
|
|||
| RA Capital Management, L.P. | 17.1% | ||||
| Peter Kolchinsky | 17.1% | ||||
| Rajeev Shah | 17.1% | ||||
| RA Capital Healthcare Fund, L.P. | 17.1% | ||||
|
OnKure Therapeutics, Inc.
13G
OKUR · 68277Q105
|
9.9% |
4/7/2026
Event 3/31/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Zai Lab Limited
13G
ZLAB · 98887Q104
|
5.2% |
4/6/2026
Event 3/30/2026
|
|||
| RA Capital Management, L.P. | 5.2% | ||||
| Peter Kolchinsky | 5.2% | ||||
| Rajeev Shah | 5.2% | ||||
| RA Capital Healthcare Fund, L.P. | 5.2% | ||||
|
Xencor, Inc.
13G
XNCR · 98401F105
|
6.5% |
3/30/2026
Event 3/23/2026
|
|||
| RA Capital Management, L.P. | 6.5% | ||||
| Peter Kolchinsky | 6.5% | ||||
| Rajeev Shah | 6.5% | ||||
| RA Capital Healthcare Fund, L.P. | 6.5% | ||||
|
Equillium, Inc.
13G
EQ · 29446K106
|
9.9% |
3/20/2026
Event 3/13/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Acumen Pharmaceuticals, Inc.
13D/A
ABOS · 00509G209
|
29.5% |
3/17/2026
Event 3/13/2026
|
|||
| RA Capital Management, L.P. | 29.5% | ||||
| Peter Kolchinsky | 29.5% | ||||
| Rajeev Shah | 29.5% | ||||
| RA Capital Healthcare Fund, L.P. | 26.8% | ||||
|
Bicara Therapeutics Inc.
13D/A
BCAX · 055477103
|
11.5% |
3/2/2026
Event 2/26/2026
|
|||
| RA Capital Management, L.P. | 11.5% | ||||
| Peter Kolchinsky | 11.5% | ||||
| Rajeev Shah | 11.5% | ||||
| RA Capital Healthcare Fund, L.P. | 7.3% | ||||
|
Evommune, Inc.
13D/A
EVMN · 30054Y107
|
9.7% |
2/17/2026
Event 2/12/2026
|
|||
| RA Capital Management, L.P. | 9.7% | ||||
| Peter Kolchinsky | 9.7% | ||||
| Rajeev Shah | 9.7% | ||||
| RA Capital Healthcare Fund, L.P. | 7.5% | ||||
|
Spyglass Pharma, Inc.
13D
SGP · 85220G109
|
24.1% |
2/17/2026
Event 2/9/2026
|
|||
| RA Capital Management, L.P. | 24.1% | ||||
| Peter Kolchinsky | 24.1% | ||||
| Rajeev Shah | 24.1% | ||||
| RA Capital Healthcare Fund, L.P. | 17.9% | ||||
| RA Capital Nexus Fund III, L.P. | 6.2% | ||||
|
Surrozen, Inc.
13G/A
SRZN · 86889P208
|
9.2% |
2/17/2026
Event 12/31/2025
|
|||
| RA Capital Management, L.P. | 9.2% | ||||
| Peter Kolchinsky | 9.2% | ||||
| Rajeev Shah | 9.2% | ||||
| RA Capital Healthcare Fund, L.P. | 9.2% | ||||
|
Rhythm Pharmaceuticals, Inc.
13G/A
RYTM · 76243J105
|
9.9% |
2/17/2026
Event 12/31/2025
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Monopar Therapeutics Inc.
13G/A
MNPR · 61023L207
|
9.9% |
2/17/2026
Event 12/31/2025
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
LB Pharmaceuticals Inc
13G/A
LBRX · 50180M108
|
8.7% |
2/17/2026
Event 12/31/2025
|
|||
| RA Capital Management, L.P. | 8.7% | ||||
| Peter Kolchinsky | 8.7% | ||||
| Rajeev Shah | 8.7% | ||||
| RA Capital Healthcare Fund, L.P. | 8.7% | ||||
|
Larimar Therapeutics, Inc.
13G/A
LRMR · 517125100
|
0% |
2/17/2026
Event 12/31/2025
|
|||
| RA Capital Management, L.P. | 0% | ||||
| Peter Kolchinsky | 0% | ||||
| Rajeev Shah | 0% | ||||
| RA Capital Healthcare Fund, L.P. | 0% | ||||
|
Eledon Pharmaceuticals, Inc.
13G/A
ELDN · 28617K101
|
0% |
2/17/2026
Event 12/31/2025
|
|||
| RA Capital Management, L.P. | 0% | ||||
| Peter Kolchinsky | 0% | ||||
| Rajeev Shah | 0% | ||||
| RA Capital Healthcare Fund, L.P. | 0% | ||||
|
Arcellx, Inc.
13G/A
ACLX · 03940C100
|
2.2% |
2/17/2026
Event 12/31/2025
|
|||
| RA Capital Management, L.P. | 2.2% | ||||
| Peter Kolchinsky | 2.2% | ||||
| Rajeev Shah | 2.2% | ||||
| RA Capital Healthcare Fund, L.P. | 2.2% | ||||
|
ALX Oncology Holdings Inc.
13G
ALXO · 00166B105
|
9.9% |
2/9/2026
Event 2/2/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Helix Acquisition Corp. III
13G
HLXC · G4444S107
|
7.0% |
2/2/2026
Event 1/26/2026
|
|||
| RA Capital Management, L.P. | 7.0% | ||||
| Peter Kolchinsky | 7.0% | ||||
| Rajeev Shah | 7.0% | ||||
| RA Capital Healthcare Fund, L.P. | 7.0% | ||||
|
Century Therapeutics, Inc.
13G
IPSC · 15673T100
|
9.9% |
1/16/2026
Event 1/9/2026
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Cidara Therapeutics, Inc.
13D/A
CDTX · 171757206
|
0% |
1/9/2026
Event 1/7/2026
|
|||
| RA Capital Management, L.P. | 0% | ||||
| Peter Kolchinsky | 0% | ||||
| Rajeev Shah | 0% | ||||
| RA Capital Healthcare Fund, L.P. | 0% | ||||
|
Disc Medicine, Inc.
13G
IRON · 254604101
|
5.9% |
1/7/2026
Event 12/30/2025
|
|||
| RA Capital Management, L.P. | 5.9% | ||||
| Peter Kolchinsky | 5.9% | ||||
| Rajeev Shah | 5.9% | ||||
| RA Capital Healthcare Fund, L.P. | 5.9% | ||||
|
Rezolute, Inc.
13G
RZLT · 76200L309
|
9.9% |
12/18/2025
Event 12/11/2025
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 9.9% | ||||
|
Perceptive Capital Solutions Corp
13D
PCSC · G70077105
|
8.4% |
12/12/2025
Event 12/5/2025
|
|||
| RA Capital Management, L.P. | 8.4% | ||||
| Peter Kolchinsky | 8.4% | ||||
| Rajeev Shah | 8.4% | ||||
| RA Capital Healthcare Fund, L.P. | 8.4% | ||||
|
Benitec Biopharma Inc.
13G
BNTC · 08205P209
|
5.5% |
12/3/2025
Event 11/7/2025
|
|||
| RA Capital Management, L.P. | 5.5% | ||||
| Peter Kolchinsky | 5.5% | ||||
| Rajeev Shah | 5.5% | ||||
| RA Capital Healthcare Fund, L.P. | 5.5% | ||||
|
Tourmaline Bio, Inc.
13G/A
TRML · 89157D105
|
0% |
11/14/2025
Event 9/30/2025
|
|||
| RA Capital Management, L.P. | 0% | ||||
| Peter Kolchinsky | 0% | ||||
| Rajeev Shah | 0% | ||||
| RA Capital Healthcare Fund, L.P. | 0% | ||||
|
RxSight, Inc.
13G/A
RXST · 78349D107
|
0% |
11/14/2025
Event 9/30/2025
|
|||
| RA Capital Management, L.P. | 0% | ||||
| Peter Kolchinsky | 0% | ||||
| Rajeev Shah | 0% | ||||
| RA Capital Healthcare Fund, L.P. | 0% | ||||
|
Dyne Therapeutics, Inc.
13G/A
DYN · 26818M108
|
0% |
11/14/2025
Event 9/30/2025
|
|||
| RA Capital Management, L.P. | 0% | ||||
| Peter Kolchinsky | 0% | ||||
| Rajeev Shah | 0% | ||||
| RA Capital Healthcare Fund, L.P. | 0% | ||||
|
Lenz Therapeutics, Inc.
13D/A
LENZ · 52635N103
|
13.6% |
11/7/2025
Event 11/5/2025
|
|||
| RA Capital Management, L.P. | 13.6% | ||||
| Peter Kolchinsky | 13.6% | ||||
| Rajeev Shah | 13.6% | ||||
| RA Capital Healthcare Fund, L.P. | 10.8% | ||||
|
89BIO, Inc.
13D/A
ETNB · 282559103
|
0% |
11/3/2025
Event 10/30/2025
|
|||
| RA Capital Management, L.P. | 0% | ||||
| Peter Kolchinsky | 0% | ||||
| Rajeev Shah | 0% | ||||
| RA Capital Healthcare Fund, L.P. | 0% | ||||
|
Lexeo Therapeutics, Inc.
13G
LXEO · 52886X107
|
6.9% |
10/27/2025
Event 10/20/2025
|
|||
| RA Capital Management, L.P. | 6.9% | ||||
| Peter Kolchinsky | 6.9% | ||||
| Rajeev Shah | 6.9% | ||||
| RA Capital Healthcare Fund, L.P. | 6.9% | ||||
|
Jade Biosciences, Inc.
13G
JBIO · 008064206
|
7.0% |
10/16/2025
Event 10/8/2025
|
|||
| RA Capital Management, L.P. | 7.0% | ||||
| Peter Kolchinsky | 7.0% | ||||
| Rajeev Shah | 7.0% | ||||
| RA Capital Healthcare Fund, L.P. | 7.0% | ||||
|
Ars Pharmaceuticals, Inc.
13D/A
SPRY · 82835W108
|
11.1% |
10/1/2025
Event 9/29/2025
|
|||
| RA Capital Management, L.P. | 11.1% | ||||
| Peter Kolchinsky | 11.1% | ||||
| Rajeev Shah | 11.1% | ||||
| RA Capital Healthcare Fund, L.P. | 10.1% | ||||
|
Pepgen Inc.
13D/A
PEPG · 713317105
|
29.2% |
9/30/2025
Event 9/26/2025
|
|||
| RA Capital Management, L.P. | 29.2% | ||||
| Peter Kolchinsky | 29.2% | ||||
| Rajeev Shah | 29.2% | ||||
| RA Capital Healthcare Fund, L.P. | 27.0% | ||||
|
Mineralys Therapeutics, Inc.
13D/A
MLYS · 603170101
|
9.9% |
9/8/2025
Event 9/4/2025
|
|||
| RA Capital Management, L.P. | 9.9% | ||||
| Peter Kolchinsky | 9.9% | ||||
| Rajeev Shah | 9.9% | ||||
| RA Capital Healthcare Fund, L.P. | 7.5% | ||||
|
Adagio Medical Holdings, Inc.
13G/A
ADGM · 00534B100
|
7.2% |
8/26/2025
Event 6/30/2025
|
|||
| RA Capital Management, L.P. | 7.2% | ||||
| Peter Kolchinsky | 7.2% | ||||
| Rajeev Shah | 7.2% | ||||
| RA Capital Healthcare Fund, L.P. | 6.9% | ||||
|
Assembly Biosciences, Inc.
13G
ASMB · 045396207
|
9.5% |
8/18/2025
Event 8/11/2025
|
|||
| RA Capital Management, L.P. | 9.5% | ||||
| Peter Kolchinsky | 9.5% | ||||
| Rajeev Shah | 9.5% | ||||
| RA Capital Healthcare Fund, L.P. | 9.5% | ||||
|
Verona Pharma plc
13G/A
VRNA · 925050106
|
0.7% |
8/14/2025
Event 6/30/2025
|
|||
| RA Capital Management, L.P. | 0.7% | ||||
| Peter Kolchinsky | 0.7% | ||||
| Rajeev Shah | 0.7% | ||||
| RA Capital Healthcare Fund, L.P. | 0.7% | ||||
|
Urogen Pharma Ltd.
13G/A
URGN · M96088105
|
0% |
8/14/2025
Event 6/30/2025
|
|||
| RA Capital Management, L.P. | 0% | ||||
| Peter Kolchinsky | 0% | ||||
| Rajeev Shah | 0% | ||||
| RA Capital Healthcare Fund, L.P. | 0% | ||||
|
Sutro Biopharma, Inc.
13G/A
STRO · 869367102
|
0% |
8/14/2025
Event 6/30/2025
|
|||
| RA Capital Management, L.P. | 0% | ||||
| Peter Kolchinsky | 0% | ||||
| Rajeev Shah | 0% | ||||
| RA Capital Healthcare Fund, L.P. | 0% | ||||
|
Sera Prognostics, Inc.
13G/A
SERA · 81749D107
|
0% |
8/14/2025
Event 6/30/2025
|
|||
| RA Capital Management, L.P. | 0% | ||||
| Peter Kolchinsky | 0% | ||||
| Rajeev Shah | 0% | ||||
| RA Capital Healthcare Fund, L.P. | 0% | ||||
|
Protara Therapeutics, Inc.
13G/A
TARA · 74365U107
|
4.9% |
8/14/2025
Event 6/30/2025
|
|||
| RA Capital Management, L.P. | 4.9% | ||||
| Peter Kolchinsky | 4.9% | ||||
| Rajeev Shah | 4.9% | ||||
| RA Capital Healthcare Fund, L.P. | 4.9% | ||||
|
Day One Biopharmaceuticals, Inc.
13G/A
DAWN · 23954D109
|
0% |
8/14/2025
Event 6/30/2025
|
|||
| RA Capital Management, L.P. | 0% | ||||
| Peter Kolchinsky | 0% | ||||
| Rajeev Shah | 0% | ||||
| RA Capital Healthcare Fund, L.P. | 0% | ||||
|
Boundless Bio, Inc.
13G/A
BOLD · 10170A100
|
0% |
8/14/2025
Event 6/30/2025
|
|||
| RA Capital Management, L.P. | 0% | ||||
| Peter Kolchinsky | 0% | ||||
| Rajeev Shah | 0% | ||||
| RA Capital Healthcare Fund, L.P. | 0% | ||||
|
Astria Therapeutics, Inc.
13G/A
ATXS · 04635X102
|
0% |
8/14/2025
Event 6/30/2025
|
|||
| RA Capital Management, L.P. | 0% | ||||
| Peter Kolchinsky | 0% | ||||
| Rajeev Shah | 0% | ||||
| RA Capital Healthcare Fund, L.P. | 0% | ||||
|
Alector, Inc.
13G/A
ALEC · 014442107
|
0% |
8/14/2025
Event 6/30/2025
|
|||
| RA Capital Management, L.P. | 0% | ||||
| Peter Kolchinsky | 0% | ||||
| Rajeev Shah | 0% | ||||
| RA Capital Healthcare Fund, L.P. | 0% | ||||